Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction Pathway
- 1 August 1999
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 17 (3) , 241-258
- https://doi.org/10.1023/a:1006380320290
Abstract
The year 2000 will be a significant date for the field of Ras-related therapies since numerous agents will have Phase II clinical efficacy data maturing to provide proof of principle for this cancer treatment strategy. These data will also provide an important milestone for the cancer research community since these molecules represent a small vanguard of oncology drug discovery projects predicated on molecular targets. We can only hope that these agents are a successful harbinger for the formidable number of targeted therapies that will be entering development pipelines in the coming years.Keywords
This publication has 108 references indexed in Scilit:
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1Published by Wiley ,2000
- Abrogation of c-Raf expression induces apoptosis in tumor cellsOncogene, 1998
- Modification of Mutant K-ras Gene Expression in Non-Small Cell Lung Cancer (NSCLC). University of Texas M.D. Anderson Cancer Center, Houston, TexasHuman Gene Therapy, 1996
- Differential Effects of Monoterpenes and Lovastatin on RAS ProcessingJournal of Biological Chemistry, 1995
- Transformation of Mammalian Cells by Constitutively Active MAP Kinase KinaseScience, 1994
- Complexes of Ras⋅GTP with Raf-1 and Mitogen-Activated Protein Kinase KinaseScience, 1993
- Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- rasScience, 1993
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesPublished by Elsevier ,1988
- ras GENESAnnual Review of Biochemistry, 1987